ROLE OF L-CARNITINE IN CONGESTIVE CARDIAC FAILURE
Main Article Content
Objective: To determine the effect of L- Carnitine on functional and echocardiographic parameters of
patients with congestive cardiac failure (CCF).
Material and Methods: This double-blinded placebo control trial was conducted on 100 cases of CCF at
cardiology outdoor department from March 2006 to May 2006. Subjects were randomized into group A
(n=50) receiving 1 gm L-Carnitine and group B (n=50) receiving placebo. Baseline and at three months
follow-up clinical and echocardiographic data of subjects was recorded.
Results: In L-Carnitine vs. placebo, 6 minutes walk was 400 + 87 m vs. 360 + 85 m (p = 0.04), NYHA
class II and III improved (p= 0.7, p=0.3 respectively), LVED dimension showed no significant improvement
(5.8 + 0.7 cm vs. 5.7 + 0.7 cm, p= 0.69), and FS improved (18.37 + 3.4 vs.19.90 + 6.7, p= 0.03). The 6
minutes walk and FS improved in ischemic vs. Congestive cardiomyopathy (412 + 74 vs. 374 + 108
meters, p= 0.3), (19.2 + 50 % vs.15.9 + 3.6 %, p=0.03). In ischemic cardiomyopathy 6 minutes walk
improved (p= 0.001), LVED dimension increased (p=0.24), FS improved (p= 0.50) and NYHA class II
(p=0.001), and III (p=0.02) improved. In congestive cardiomyopathy 6 minutes walk improved from
baseline (p=0.13), FS showed no improvement (p=0.23), LVED dimension was not affected significantly
(p= 0.65). NYHA class improved (p=0.05).
Conclusion: L- carnitine is beneficial in the treatment of congestive cardiac failure. It is more effective
in ischemic as compared to congestive cardiomyopathy.
Work published in JPMI is licensed under a
Creative Commons Attribution-NonCommercial 2.0 Generic License.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.